Mavyret

Mavyret (glecaprevir/pibrentasvir) is an oral combination antiviral medication made by AbbVie for the treatment of chronic hepatitis C virus (HCV) infection. It combines two direct-acting antivirals (DAAs) — glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) — into a once-daily pill that can cure hepatitis C in as few as 8 weeks for most patients.

Without insurance, a full course of Mavyret can cost more than $24,000. AbbVie offers patient assistance programs to help qualifying patients access Mavyret.

How to Afford Mavyret

• Uninsured patients who meet income requirements may receive Mavyret at no cost through myAbbVie Assist.
• Commercially insured patients with high out-of-pocket costs can use the Mavyret Savings Card.
• State Medicaid programs in many states now cover Mavyret with fewer restrictions than before, due to federal pressure and litigation.

ClariMeds will identify the right free program for Mavyret for your situation and handle the application from start to finish.

What Does Mavyret Treat?

Mavyret is FDA-approved to treat:

• Chronic HCV infection in adults and pediatric patients (3 years and older) with all HCV genotypes (1–6) — pan-genotypic coverage eliminates the need to identify the specific genotype before starting treatment
• Treatment-naive patients (no prior HCV treatment) with compensated cirrhosis or without cirrhosis — 8 weeks
• Prior treatment-experienced patients (who received pegylated interferon/ribavirin or sofosbuvir-based regimens) — 8–16 weeks depending on prior therapy and cirrhosis status

Mavyret is the first 8-week pan-genotypic cure for hepatitis C in treatment-naive patients without cirrhosis.

How Mavyret Works

HCV replicates inside liver cells using viral proteins — NS3/4A protease and NS5A — that are essential for processing viral proteins and replicating the genome. Glecaprevir blocks NS3/4A protease, which is required to cleave the HCV polyprotein into functional viral proteins; pibrentasvir blocks NS5A, a protein involved in RNA replication and viral assembly. By targeting two separate stages in the HCV lifecycle simultaneously, Mavyret achieves sustained virologic response (SVR) rates above 97% across all genotypes — meaning the virus is undetectable 12 weeks after completing treatment, which is considered a functional cure.